<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053439</url>
  </required_header>
  <id_info>
    <org_study_id>CHIP Lymphoma</org_study_id>
    <nct_id>NCT04053439</nct_id>
  </id_info>
  <brief_title>Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications</brief_title>
  <official_title>A Single Centre Cohort Study to Determine if Clonal Hematopoieses of Indeterminate Potential (CHIP) is a Risk Factor for Chemotherapy-Related Complications in Lymphoma Patients &gt;= 60 Receiving Cytotoxic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in
      bone marrow stem cells that give that population of cells a survival or 'clonal' advantage
      for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older
      is a risk factor for chemotherapy-related complications like low blood counts, infections,
      cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover
      normal blood counts after chemotherapy finishes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance (1-4). Up to 20% of
      individuals in the general population acquire mutations in their bone marrow stem cells as
      they age that give that population of cells a survival or 'clonal' advantage for growth. The
      frequency of CHIP may be higher in patients with other cancers. CHIP increases with age, and
      has been shown to be a risk factor associated with cardiovascular disease and a tendency to
      the development of bone marrow cancers at a rate of 1% per year (1,2,5). CHIP is also
      associated with the development of bone marrow cancers that occur after chemotherapy. The
      investigators want to investigate whether CHIP is also a risk factor for chemotherapy-related
      complications like low blood counts, infections, cardiac events, hospitalizations, dose
      delays and dose reductions. They are also interested in determining if CHIP may explain why
      some patients do not recover normal blood counts after chemotherapy finishes.

      The results from this study may help physicians better understand why some people have
      difficulty with chemotherapy (in the short and long-term) while others do not. Screening for
      CHIP in older patients may become a recommended standard that allows physicians to tailor
      anti-cancer treatment to the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if CHIP is an independent risk factor for chemotherapy-induced complications.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Complications during chemotherapy defined as any or all of the following: febrile neutropenia, new grades 3-4 anemia, thrombocytopenia and neutropenia immediately (day -1 or 0) preceding next cycle of chemotherapy, secondary dose reductions or dose delays due to myelosuppression or toxicity, cardiovascular toxicity (arrhythmias, congestive heart failure, symptomatic coronary disease), secondary granulocyte colony-stimulating factor (GCSF) use due to neutropenia, inability to complete all scheduled cycles due to chemotherapy related complications, dose delays that exceed 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emerging dysmyelopoiesis after chemotherapy</measure>
    <time_frame>Up to 12 months after completion of chemotherapy</time_frame>
    <description>The number of patients with and without CHIP who, following at 6 and 12 months post chemotherapy have:
Hemoglobin, white blood cell (WBC) or platelet (PLT) count that does not recover to normal pre-chemotherapy levels
Persistant macrocytosis defined as mean cell volume (MCV) &gt; 96 fl
Persistant anisocytosis defined as red cell distribution width (RDW) &gt; 14.5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expansion of clonal hematopoietic stem cells</measure>
    <time_frame>Up to 5 years after completion of chemotherapy</time_frame>
    <description>Expansion of clonal hematopoietic stem cells over time measured using next generation sequencing of 40 myeloid genes in patients with CHIP at baseline defined by variant allele frequency (VAF) that increases by 10% of more or the emergence of new clones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of therapy-related myeloid neoplasm</measure>
    <time_frame>Up to 5 years after completion of chemotherapy</time_frame>
    <description>Therapy-related myeloid neoplasm defined as any of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), MDS/MPN diagnosed by bone marrow exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years after completion of chemotherapy</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Lymphoma</condition>
  <condition>Chemotherapeutic Toxicity</condition>
  <arm_group>
    <arm_group_label>Lymphoma patients &gt;=60 receiving cytotoxic chemotherapy</arm_group_label>
    <description>Lymphoma patients &gt;=60 receiving cytotoxic chemotherapy who have consented to DNA extraction and analysis for CHIP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test for determination of CHIP</intervention_name>
    <description>Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.</description>
    <arm_group_label>Lymphoma patients &gt;=60 receiving cytotoxic chemotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A peripheral blood ethylenediaminetetraacetic acid (EDTA) tube will be used to obtain blood
      for DNA extraction.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly patients (&gt;= 60 years old) being treated at a tertiary cancer centre in Toronto,
        ON.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a lymphoma (ex: diffuse large B cell lymphoma (DLBCL), follicular
             lymphoma, marginal zone lymphoma, small lymphocytic lymphoma/chronic lymphocytic
             leukemia, Hodgkin's lymphoma, peripheral T cell lymphoma, anaplastic large cell
             lymphoma, angioimmunoblastic lymphoma, hairy cell leukemia, Waldenstrom's
             macroglobulinemia, anaplastic large cell lymphoma, small lymphocytic lymphoma/chronic
             lymphocytic leukemia, and mantle cell lymphoma).

          -  Commencing first or second-line cytotoxic chemotherapy for lymphoma with or without
             rituximab [ex: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),
             cyclophosphamide, vincristine and prednisone (CVP), Fludarabine, fludarabine
             cyclophosphamide (FC), Bendamustine, cisplatin, cytarabine, dexamethasone (DHAP),
             etoposide, cytarabine, cisplatin, prednisone (ESHAP), gemcitabine, cisplatin and
             dexamethasone (GDP), Cladribine, Cyclophosphamide, Epirubicin, Vincristine, Prednisone
             (CEOP), dose-adjusted Dose-adjusted etoposide, prednisone, vincristine,
             cyclophosphamide, doxorubicin (DA-EPOCH)]

        Exclusion Criteria:

          -  Pre-existing diagnosis of myeloid neoplasm

          -  Circulating lymphocyte count &gt; 10 x 109/L

          -  Significant uncontrolled renal or hepatic impairment [&gt;1.5 x upper limit of normal
             (ULN) bilirubin, &gt;1.5 x ULN Alanine aminotransferase (ALT), &gt;1.5 x ULN creatinine]

          -  HIV

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rena Buckstein, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hubert Tsui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Rauh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arlene Mete</last_name>
    <phone>(416) 480-6100</phone>
    <phone_ext>3835</phone_ext>
    <email>arlene.mete@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rena Buckstein, MD</last_name>
      <phone>416-480-5847</phone>
      <email>rena.buckstein@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.</citation>
    <PMID>25426837</PMID>
  </reference>
  <reference>
    <citation>Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M, Höglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg H, Hultman CM, McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014 Dec 25;371(26):2477-87. doi: 10.1056/NEJMoa1409405. Epub 2014 Nov 26.</citation>
    <PMID>25426838</PMID>
  </reference>
  <reference>
    <citation>McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J; Understanding Society Scientific Group, Crawley C, Craig J, Scott MA, Hodkinson C, Baxter J, Rad R, Forsyth DR, Quail MA, Zeggini E, Ouwehand W, Varela I, Vassiliou GS. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015 Mar 3;10(8):1239-45. doi: 10.1016/j.celrep.2015.02.005. Epub 2015 Feb 26.</citation>
    <PMID>25732814</PMID>
  </reference>
  <reference>
    <citation>Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC, Walter MJ, Mardis ER, Dipersio JF, Chen F, Wilson RK, Ley TJ, Ding L. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014 Dec;20(12):1472-8. doi: 10.1038/nm.3733. Epub 2014 Oct 19.</citation>
    <PMID>25326804</PMID>
  </reference>
  <reference>
    <citation>Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 2;126(1):9-16. doi: 10.1182/blood-2015-03-631747. Epub 2015 Apr 30.</citation>
    <PMID>25931582</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clonal Hematopoiesis of Indeterminate Significance</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Chemotherapy complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

